Alebund Pharmaceuticals Funding: $60M Raised, Series B
Alebund Pharmaceuticals is based in Shanghai, China. It has raised $60M in total funding. Latest round: Series B.
Alebund Pharmaceuticals funding overview
Alebund Pharmaceuticals is based in Shanghai, China. Alebund Pharmaceuticals has raised $60M in total disclosed funding. That places its disclosed total in the $25M–$100M range. Its most recent disclosed round is a Series B announced in May 2021. The round record for Alebund Pharmaceuticals runs through 2021; nothing later has been disclosed. Investors on record include Quan Capital, 3E Bioventures Capital, Sherpa Healthcare Partners, Lilly Asia Ventures, Med-Fine Capital. 5 distinct backers are named across the disclosed rounds.
Alebund Pharmaceuticals at a glance
Total raised
$60M
Latest round
Series B
Latest round date
May 2021
Headquarters
Shanghai, China
Notable investors
Quan Capital, 3E Bioventures Capital, Sherpa Healthcare Partners, Lilly Asia Ventures, Med-Fine Capital
Frequently asked about Alebund Pharmaceuticals funding
How much has Alebund Pharmaceuticals raised?
Alebund Pharmaceuticals has raised $60M in total disclosed funding across the rounds on record.
Who has invested in Alebund Pharmaceuticals?
Quan Capital, 3E Bioventures Capital, Sherpa Healthcare Partners, Lilly Asia Ventures, Med-Fine Capital are named among the investors backing Alebund Pharmaceuticals.
What was the latest Alebund Pharmaceuticals funding round?
The most recent disclosed round is a Series B, announced in May 2021.
Where is Alebund Pharmaceuticals based?
Alebund Pharmaceuticals is based in Shanghai, China.
When did Alebund Pharmaceuticals last raise?
The last disclosed Alebund Pharmaceuticals round closed in May 2021 at Series B.
Round data for Alebund Pharmaceuticals is compiled from public filings and announcements; blank fields mean nothing has been disclosed rather than nothing exists. Continue with the companies in Shanghai and backer lists below.
